BJX1 Stock Overview Develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
BioLife Solutions, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for BioLife Solutions Historical stock prices Current Share Price US$27.00 52 Week High US$27.20 52 Week Low US$14.00 Beta 1.92 1 Month Change 7.14% 3 Month Change 26.17% 1 Year Change 73.08% 3 Year Change 3.93% 5 Year Change 107.69% Change since IPO 1,335.41%
Recent News & Updates
Biolife Solutions Inc. Appoints Tony J. Hunt to Its Board of Directors, Effective from January 2, 2025 Dec 16
Standex International Corporation (NYSE:SXI) acquired Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $6.2 million. Nov 15
Third quarter 2024 earnings released: US$0.037 loss per share (vs US$0.67 loss in 3Q 2023) Nov 13
BioLife Solutions, Inc. Revises Earnings Guidance for the Year 2024 Nov 13
An undisclosed buyer acquired SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS). Nov 12
BioLife Solutions, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 01 See more updates
Biolife Solutions Inc. Appoints Tony J. Hunt to Its Board of Directors, Effective from January 2, 2025 Dec 16
Standex International Corporation (NYSE:SXI) acquired Custom Biogenic Systems Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $6.2 million. Nov 15
Third quarter 2024 earnings released: US$0.037 loss per share (vs US$0.67 loss in 3Q 2023) Nov 13
BioLife Solutions, Inc. Revises Earnings Guidance for the Year 2024 Nov 13
An undisclosed buyer acquired SciSafe Holdings, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS). Nov 12
BioLife Solutions, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 01
New minor risk - Profitability Aug 12
No longer forecast to breakeven Aug 12
Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.23 loss in 2Q 2023) Aug 09
BioLife Solutions, Inc. Updates Revenue Guidance for the Year 2024 Aug 09
Now 20% undervalued Jul 31
BioLife Solutions, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Jul 26
BioLife Solutions, Inc., Annual General Meeting, Aug 01, 2024 Jun 08
Now 20% undervalued Jun 03
BioLife Solutions Introduces the CellSeal CryoCase™ at International Society for Cell & Gene Therapies (ISCT) Conference in Vancouver May 30
No longer forecast to breakeven May 15
First quarter 2024 earnings released: US$0.23 loss per share (vs US$0.32 loss in 1Q 2023) May 10
BioLife Solutions, Inc. to Report Q1, 2024 Results on May 09, 2024 May 01
An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS) for $2.6 million. Apr 20 An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. (NasdaqCM:BLFS). Apr 19
Lead Director recently sold €173k worth of stock Mar 14
Full year 2023 earnings released: US$1.52 loss per share (vs US$3.29 loss in FY 2022) Mar 01
Forecast breakeven date pushed back to 2026 Mar 01
BioLife Solutions, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 21
Third quarter 2023 earnings released: US$0.67 loss per share (vs US$0.23 loss in 3Q 2022) Nov 10
BioLife Solutions, Inc. to Report Q3, 2023 Results on Nov 09, 2023 Nov 03 BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC
Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023 Aug 11
Second quarter 2023 earnings released: US$0.23 loss per share (vs US$1.72 loss in 2Q 2022) Aug 11
BioLife Solutions, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 29 BioLife Solutions, Inc., Annual General Meeting, Jul 21, 2023
BioLife Solutions, Inc. announced delayed 10-Q filing May 12
First quarter 2023 earnings released: US$0.32 loss per share (vs US$0.17 loss in 1Q 2022) May 11
Biolife Solutions, Inc. Reaffirms Earnings Guidance for the Fiscal 2023 May 11
Chairman & CEO recently sold €59k worth of stock Apr 11
Full year 2022 earnings released: US$3.29 loss per share (vs US$0.20 loss in FY 2021) Mar 18
Chairman & CEO recently sold €91k worth of stock Mar 05
Director recently sold €82k worth of stock Jan 26
Director recently sold €82k worth of stock Jan 22
President & COO recently sold €462k worth of stock Nov 16
Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.002 profit in 3Q 2021) Nov 11
BioLife Solutions, Inc. Updates Revenue Guidance of 2022 Nov 10
BioLife Solutions, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 03
President & COO recently sold €198k worth of stock Oct 12
BioLife Solutions, Inc. Announces Executive Changes Oct 04
BioLife Solutions Appoints Cell Therapy Executive Timothy L. Moore to its Board of Directors Aug 27 Biolife Solutions Appoints Cell Therapy Executive Timothy L. Moore to Its Board of Directors Aug 26
Second quarter 2022 earnings released: US$1.71 loss per share (vs US$0.20 profit in 2Q 2021) Aug 11
BioLife Solutions, Inc. Provides Revenue Guidance for the Year 2022 Aug 10
BioLife Solutions, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 03
President & COO recently sold €144k worth of stock Jul 15
BioLife Solutions, Inc. Deploys SciSafe's Ultra Low Controlled Temperature Trailers to Extend Domestic Cold Chain Services Jun 10 Biolife Solutions, Inc. Affirms Revenue Guidance for the Year 2022 May 10
BioLife Solutions, Inc. to Report Q1, 2022 Results on May 09, 2022 May 03
BioLife Solutions, Inc., Annual General Meeting, Jun 09, 2022 May 02 BioLife Solutions, Inc. announced delayed annual 10-K filing Mar 04
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Mar 02
BioLife Solutions, Inc. Provides Revenue Guidance for 2022 Mar 01
BioLife Solutions, Inc. to Report Q4, 2021 Results on Feb 28, 2022 Feb 22
President & COO recently sold €293k worth of stock Jan 12
Third quarter 2021 earnings released: EPS US$0.002 (vs US$0.036 loss in 3Q 2020) Nov 12
CFO & Secretary recently sold €91k worth of stock Oct 28
Chairman & CEO recently sold €111k worth of stock Oct 20
BioLife Solutions, Inc. (NasdaqCM:BLFS) completed the acquisition of the remaining unknown majority stake in Sexton Biotechnologies. Sep 02
Independent Director recently sold €84k worth of stock Aug 29
CFO & Secretary recently sold €391k worth of stock Aug 20
Second quarter 2021 earnings released: EPS US$0.21 (vs US$0.70 loss in 2Q 2020) Aug 13
BioLife Solutions, Inc. Revises Revenue Guidance for the Full Year of Fiscal Year 2021 Aug 13
BioLife Solutions, Inc. (NasdaqCM:BLFS) entered into an agreement to acquire an unknown majority stake in Sexton Biotechnologies for $24.7 million. Aug 11
Chief Revenue Officer recently sold €97k worth of stock Jul 27
Chief Revenue Officer recently sold €97k worth of stock Jul 24
Independent Non-Executive Chairman Raymond Cohen has left the company Jul 15 BioLife Solutions, Inc.(NasdaqCM:BLFS) dropped from Russell 2000 Growth-Defensive Index
First quarter 2021 earnings released: US$0.034 loss per share (vs US$1.02 profit in 1Q 2020) May 15
Biolife Solutions, Inc. Updates Earnings Guidance for the Full Year 2021 May 14
BioLife Solutions, Inc. (NasdaqCM:BLFS) completed the acquisition of Global Cooling, Inc. May 04
President recently sold €113k worth of stock Mar 31
Full year 2020 earnings released: EPS US$0.098 (vs US$0.085 loss in FY 2019) Mar 24
BioLife Solutions, Inc. Provides Revenue Guidance for 2021 Mar 23
BioLife Solutions, Inc. to Report Q4, 2020 Results on Mar 22, 2021 Mar 11
New 90-day low: €30.32 Mar 07
Chief Marketing Officer recently sold €189k worth of stock Feb 23
BioLife Solutions, Inc. Announces Promotion of Marcus Schulz to the Position of Chief Revenue Officer Feb 17
Insider recently sold €1.6m worth of stock Feb 10 Shareholder Returns BJX1 DE Life Sciences DE Market 7D 3.1% 5.1% 2.0% 1Y 73.1% 2.9% 15.2%
See full shareholder returns
Return vs Market: BJX1 exceeded the German Market which returned 14.1% over the past year.
Price Volatility Is BJX1's price volatile compared to industry and market? BJX1 volatility BJX1 Average Weekly Movement 8.0% Life Sciences Industry Average Movement 7.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: BJX1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BJX1's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Show more BioLife Solutions, Inc. Fundamentals Summary How do BioLife Solutions's earnings and revenue compare to its market cap? BJX1 fundamental statistics Market cap €1.26b Earnings (TTM ) -€47.52m Revenue (TTM ) €141.23m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) BJX1 income statement (TTM ) Revenue US$146.96m Cost of Revenue US$91.81m Gross Profit US$55.15m Other Expenses US$104.59m Earnings -US$49.44m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.07 Gross Margin 37.53% Net Profit Margin -33.65% Debt/Equity Ratio 6.2%
How did BJX1 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 06:38 End of Day Share Price 2025/01/30 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources BioLife Solutions, Inc. is covered by 20 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert Wasserman Benchmark Company George Zavoico B. Riley Securities, Inc. Matthew Hewitt Craig-Hallum Capital Group LLC
Show 17 more analysts 
